| Drug General Information |
| Drug ID |
D0C0SZ
|
| Former ID |
DNCL002290
|
| Drug Name |
PRT6207
|
| Indication |
Cancer [ICD9: 140-229; ICD10:C00-C96]
|
Phase 1 |
[1]
|
|---|
| Target and Pathway |
| Target(s) |
Tyrosine-protein kinase SYK |
Target Info |
Modulator |
[2]
|
|---|
|
KEGG Pathway
|
NF-kappa B signaling pathway
|
|
PI3K-Akt signaling pathway
|
|
Osteoclast differentiation
|
|
Platelet activation
|
|
Natural killer cell mediated cytotoxicity
|
|
B cell receptor signaling pathway
|
|
Fc epsilon RI signaling pathway
|
|
Fc gamma R-mediated phagocytosis
|
|
Tuberculosis
|
|
Epstein-Barr virus infection
|
|
Viral carcinogenesis
|
|
PANTHER Pathway
|
B cell activation
|
|
Pathway Interaction Database
|
Fc-epsilon receptor I signaling in mast cells
|
|
BCR signaling pathway
|
|
GMCSF-mediated signaling events
|
|
Atypical NF-kappaB pathway
|
|
Osteopontin-mediated events
|
|
FAS (CD95) signaling pathway
|
|
Thromboxane A2 receptor signaling
|
|
IL2-mediated signaling events
|
|
Class I PI3K signaling events
|
|
Alpha-synuclein signaling
|
|
PathWhiz Pathway
|
Fc Epsilon Receptor I Signaling in Mast Cells
|
|
Reactome
|
GPVI-mediated activation cascade
|
|
FCGR activation
|
|
Regulation of actin dynamics for phagocytic cup formation
|
|
Role of phospholipids in phagocytosis
|
|
DAP12 signaling
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Role of LAT2/NTAL/LAB on calcium mobilization
|
|
FCERI mediated MAPK activation
|
|
FCERI mediated Ca+2 mobilization
|
|
Integrin alphaIIb beta3 signaling
|
|
Interleukin-2 signaling
|
|
CLEC7A (Dectin-1) signaling
|
|
Dectin-2 family
|
|
Regulation of signaling by CBL
|
|
Antigen activates B Cell Receptor (BCR) leading to generation of second messengers
|
|
WikiPathways
|
IL-2 Signaling Pathway
|
|
IL-3 Signaling Pathway
|
|
Fc epsilon receptor (FCERI) signaling
|
|
Signaling by the B Cell Receptor (BCR)
|
|
Interleukin-2 signaling
|
|
Fcgamma receptor (FCGR) dependent phagocytosis
|
|
DAP12 interactions
|
|
B Cell Receptor Signaling Pathway
|
|
RANKL/RANK Signaling Pathway
|
|
Integrin alphaIIb beta3 signaling
|
|
GPVI-mediated activation cascade
|
|
Regulation of toll-like receptor signaling pathway
|
|
IL-5 Signaling Pathway
|
| References |
| REF 1 | More Than 900 Medicines and Vaccines in Clinical Testing Offer New Hope in the Fight Against Cancer. Pharmaceutical Research and Manufacturers of America report. 2012. |
|---|
| REF 2 | Advances in kinase inhibition: treating rheumatic diseases and beyond. Curr Opin Rheumatol. 2014 March; 26(2): 237-243. |
|---|
